Table 23, Summary of included studies. Comparison 22. Switching to TCA versus augmenting with mirtazapine - Further-line treatment

Warning: The NCBI web site requires JavaScript to function. more...

Study	Population	Intervention	Comparison	Details of inadequate response/treatment resistance	Comments
Navarro 2019a RCT Spain	N=112 Mean age (years): 55.5 Gender (% female): 67 Ethnicity (% BME): NR Baseline severity: HAMD 28.22 (more severe)	Imipramine target plasma level 175-300 ng/mL	Mirtazapine 30mg/day + Venlafaxine 225-300mg/day	Inadequate response (non-remission HAMD>7) to 10 weeks of treatment with venlafaxine	Treatment length (weeks): 10 Outcomes: Depression symptomatology endpoint Depression symptomatology change score Remission Discontinuation due to any reason

Study

Population

Intervention

Comparison

Details of inadequate response/treatment resistance

Comments

RCT

Spain

N=112

Mean age (years): 55.5

Gender (% female): 67

Ethnicity (% BME): NR

Baseline severity: HAMD 28.22 (more severe)

Imipramine target plasma level 175-300 ng/mL

Mirtazapine 30mg/day + Venlafaxine 225-300mg/day

Inadequate response (non-remission HAMD>7) to 10 weeks of treatment with venlafaxine

Treatment length (weeks): 10

Outcomes:

: BME: black and minority ethnic; HAMD: Hamilton depression scale; NR: not reported; RCT: randomised controlled trial; TCA: tricyclic antidepressant

Further-line treatment: Depression in adults: Evidence review D.

NICE Guideline, No. 222.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.